Code intelligence

FDA-NDA211448 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA211448.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: MEZOFY (ARIPIPRAZOLE) — Type 3 - New Dosage Form

Policy FDA-NDA211448 · Neurology

High

MEZOFY (aripiprazole) is an oral film formulation approved under NDA211448, representing a new dosage form of an established antipsychotic agent. As an oral drug, it follows the Part D billing pathway

View alert

Audit documentation

Building an audit file that includes FDA-NDA211448?

The Tripwire Audit Pack exports 12 months of Neurology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Neurology audit pack — $349One-time purchase · not a subscription